Despite their commercial success, real-world data in wAMD show that most patients are falling short of the durability promise of the Gen 1.5 labels 1. Adapted from Durga Borkar, et al. Poster presented at ARVO 2025. Poster #3108. Treatment-Naïve Eyes (n=389 a ) Previously Treated Eyes (n=6364 a ) Faricimab injections observed after the first 6 months of treatment through Year 2 in the FARENTINA study 1 Year 2: ~4.5 Year 2: ~6 Most patients are on a Q8W-Q12W schedule in the real world in Year 2 a Only eyes with ≥ 1 injection after index and prior to censoring were included. In Year 2, patients received 4.5 injections which is an average dosing interval of every 11.5 weeks In Year 2, patients received 6.0 injections which is an average dosing interval of every 8 weeks 18